|
Effect of a genomic classifier on adjuvant treatment decision-making among patients with high-risk pathology at radical prostatectomy: Results from the multicenter prospective PRO-IMPACT study. |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - GenomeDx |
|
|
|
Stock and Other Ownership Interests - GenomeDx |
Travel, Accommodations, Expenses - GenomeDx |
|
|
|
Stock and Other Ownership Interests - GenomeDx |
Travel, Accommodations, Expenses - GenomeDx |
|
|
Consulting or Advisory Role - GenomeDx (Inst) |
|
|
No Relationships to Disclose |
|
|
Research Funding - GenomeDx (Inst) |
|
|
Speakers' Bureau - Astellas Pharma |
|
|
Honoraria - Astellas Pharma; Bayer; Dendreon; Janssen; Medivation |
Consulting or Advisory Role - Astellas Pharma; Bayer; Dendreon; Janssen; Medivation |
Speakers' Bureau - Astellas Pharma; Bayer; Dendreon; Janssen; Medivation |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); GenomeDx (Inst); Genomic Health (Inst); Janssen (Inst); Medivation (Inst); Spectrum Pharmaceuticals (Inst) |
|
|
Honoraria - Dendreon; MTG Therapeutics; profound; Sanofi; Tokai Pharmaceuticals |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - MDxhealth; Physical Optics Corporation; SonaCare Medical |
Research Funding - Abbott Molecular; Cepheid; Danone; Metabolon; pacific edge |
|
|
Consulting or Advisory Role - MDxHealth |
Research Funding - Argos Therapeutics (Inst); GenomeDx (Inst); Myriad Genetics (Inst) |
Travel, Accommodations, Expenses - MDxHealth |
|
|
Research Funding - GenomeDx |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Carolina Urology Partners |
Leadership - Carolina Urology Partners |
Stock and Other Ownership Interests - Carolina Urology Partners |
Honoraria - Astellas Pharma; Myriad Genetics |
Consulting or Advisory Role - Astellas Pharma; Myriad Genetics |
Speakers' Bureau - Astellas Pharma; Myriad Genetics |
Research Funding - Allergan; Argos Therapeutics; Astellas Pharma; Boston Scientific; Cogentix Medical; Coloplast; Dendreon; GenomeDx; Genomic Health; MDxHealth; Medivation; Myriad Genetics; Orion |
Travel, Accommodations, Expenses - Astellas Pharma; Myriad Genetics |
|
|
|
|
Stock and Other Ownership Interests - GenomeDx |
Patents, Royalties, Other Intellectual Property - CANCER DIAGNOSTICS USING BIOMARKERS 20140066323 |
Travel, Accommodations, Expenses - GenomeDx |
|
|
Consulting or Advisory Role - Astellas Pharma |
Research Funding - Genomic Health; Myriad Genetics |